HAS2 and breast carcinoma: In breast cancer, overexpression of hyaluronan synthase 2 increases ErbB2-dependent signalling leading to disease progression [14], while suppression of hyaluronan synthase 2 leads to inhibition of tumorigenesis and progression of breast cancer [15].